Immunogenicity and Safety of Sequential Immunization of Recombinant SARS-CoV-2 Fusion Protein Vaccine

NCT05238649 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

150

Enrollment

INDUSTRY

Sponsor class

Conditions

COVID-19 Pandemic

Interventions

BIOLOGICAL: Recombinant SARS-CoV-2 Fusion Protein Vaccine 10μg
BIOLOGICAL: Recombinant SARS-CoV-2 Fusion Protein Vaccine 25μg
BIOLOGICAL: SARS-Cov-2 Vaccine Inactivated

Sponsor

Livzon Pharmaceutical Group Inc.